Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

This phase 3 randomized controlled trial (AMPLITUDE-O) evaluated efpeglenatide, a weekly GLP-1 receptor agonist, in 4076 adults with type 2 diabetes and either cardiovascular disease or kidney disease with additional risk factors. Participants received subcutaneous efpeglenatide (4 mg or 6 mg) or placebo. Over a median 1.81 years, efpeglenatide significantly reduced major adverse cardiovascular events (MACE) (HR 0.73; P=0.007 for superiority) and renal composite outcomes (HR 0.68; P<0.001) compared to placebo. Adverse effects included gastrointestinal symptoms (nausea, diarrhea, constipation), but rates of serious events such as pancreatitis or thyroid neoplasms were similar across groups. Benefits were consistent regardless of SGLT2 inhibitor or metformin use. The findings suggest efpeglenatide offers cardioprotective and renoprotective effects in high-risk diabetic populations

This phase 3 randomized controlled trial (AMPLITUDE-O) evaluated efpeglenatide, a weekly GLP-1 receptor agonist, in 4076 adults with type 2 diabetes and either cardiovascular disease or kidney disease with additional risk factors. Participants received subcutaneous efpeglenatide (4 mg or 6 mg) or placebo. Over a median 1.81 years, efpeglenatide significantly reduced major adverse cardiovascular events (MACE) (HR 0.73; P=0.007 for superiority) and renal composite outcomes (HR 0.68; P<0.001) compared to placebo. Adverse effects included gastrointestinal symptoms (nausea, diarrhea, constipation), but rates of serious events such as pancreatitis or thyroid neoplasms were similar across groups. Benefits were consistent regardless of SGLT2 inhibitor or metformin use. The findings suggest efpeglenatide offers cardioprotective and renoprotective effects in high-risk diabetic populations